Ac. Desfaits et al., Gliclazide reduces the induction of human monocyte adhesion to endothelialcells by glycated albumin, DIABET OB M, 1(2), 1999, pp. 113-120
Objective: To examine the kinetic of human monocyte adhesion to endothelial
cells stimulated by glycated albumin, the contributive role of cell adhesi
on molecules to this effect, and the effect of gliclazide-an hypoglycemic d
rug with antioxidant properties-on these parameters.
Methods: In-vitro experiments performed in the presence and absence of glic
lazide consisted of: (1) time-dependent determination of human monocyte adh
esion to human endothelial cells (ECs) pre-exposed to glycated albumin; (2)
evaluation of adhesion after incubation of ECs with antibodies against cel
l surface adhesion molecules; and (3) determination of EC surface adhesion
molecules and of the activity of the transcription factor NF-kappa B.
Results: Exposition of human ECs for 1-48 h to 100 mu g/ml glycated albumin
led to a time-dependent increase in human monocyte adhesion to endothelium
. Pretreatment of ECs with 10 mu g/ml gliclazide significantly decreased th
e glycated albumin-stimulated monocyte adhesion to these cells. Anti-antibo
dies against E-selectin (ELAM-1), vascular cell adhesion molecule-1 (VCAM-1
) and intercellular adhesion molecule-1 (ICAM-1) also reduced the stimulato
ry effect of glycated albumin on monocyte adhesion. In glycated albumin-tre
ated ECs, an induction of both soluble and cell associated expression of EL
AM-1, VCAM-1 and ICAM-1, an augmentation in the levels of these molecule tr
anscripts and an increase in the DNA binding activity for NF-kappa B in the
promoters of these antigens were observed. Gliclazide markedly inhibited t
he induction of all these parameters.
Conclusions: Glycated albumin stimulates human monocyte adhesion to ECs by
inducing cell associated ELAM-1, ICAM-1 and VCAM-1. Gliclazide effectively
inhibits monocyte adhesion to ECs by reducing glycated albumin induction of
EC adhesion molecules and NF-kappa B activation. These results suggest tha
t gliclazide may be beneficial in the prevention of endothelial disturbance
s associated with hyperglycemia in diabetic patients.